Canaccord Genuity Group Lowers Delcath Systems (NASDAQ:DCTH) Price Target to $14.00

Delcath Systems (NASDAQ:DCTHGet Rating) had its target price reduced by Canaccord Genuity Group from $17.00 to $14.00 in a report released on Monday morning, The Fly reports.

Several other research analysts have also recently weighed in on the stock. StockNews.com began coverage on shares of Delcath Systems in a report on Monday. They set a sell rating on the stock. HC Wainwright lowered their price objective on shares of Delcath Systems from $25.00 to $19.00 and set a buy rating on the stock in a research report on Wednesday, August 10th. Finally, BTIG Research lowered their price objective on shares of Delcath Systems to $19.00 in a research report on Tuesday, November 15th.

Delcath Systems Stock Down 1.4 %

Shares of NASDAQ DCTH opened at $2.92 on Monday. The stock has a market capitalization of $25.11 million, a P/E ratio of -0.77 and a beta of 0.92. The company has a 50-day moving average price of $3.03 and a 200-day moving average price of $3.82. Delcath Systems has a 1 year low of $2.34 and a 1 year high of $10.24. The company has a debt-to-equity ratio of 2.55, a current ratio of 1.28 and a quick ratio of 1.15.

Delcath Systems (NASDAQ:DCTHGet Rating) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.13. Delcath Systems had a negative net margin of 757.05% and a negative return on equity of 1,396.28%. The business had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $0.82 million. During the same period in the previous year, the company earned ($0.94) earnings per share. On average, equities research analysts forecast that Delcath Systems will post -3.77 EPS for the current fiscal year.

Institutional Trading of Delcath Systems

Several hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new stake in shares of Delcath Systems in the second quarter valued at approximately $40,000. Vanguard Group Inc. raised its position in shares of Delcath Systems by 5.7% in the first quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock valued at $2,309,000 after purchasing an additional 19,605 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Delcath Systems in the first quarter valued at approximately $75,000. Cibc World Market Inc. raised its position in shares of Delcath Systems by 4.0% in the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares during the period. Finally, CI Investments Inc. bought a new stake in shares of Delcath Systems in the first quarter valued at approximately $559,000. Institutional investors own 26.18% of the company’s stock.

Delcath Systems Company Profile

(Get Rating)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Recommended Stories

The Fly logo

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.